Researchers at Linköping University show how two important cancer-related proteins can be prevented from collaborating with each other. The discovery shows the way toward future medications to combat, for example, neuroblastoma in children. Read more: https://medicalxpress.com/news/2026-04-scientists-undruggable-childhood-cancer-protein.html

The University of Queensland researchers used cutting-edge technology to map the biology of neuroblastoma—a cancer that typically develops in children under the age of 5—finding a hidden "shield" the tumors use as protection. Certain immune cells surrounding the tumor were also discovered to act as "bodyguards" for the cancer. Read more here: https://medicalxpress.com/news/2026-03-shields-bodyguards-scientists-uncover-hidden.html

Survival outcomes are comparable or better with proton beam therapy (PBT) compared with photon radiotherapy (XRT) in pediatric patients with neuroblastomas, according to findings published in Cancer Medicine . Read more: https://www.cancertherapyadvisor.com/news/proton-beam-therapy-photon-radiotherapy-pediatric-neuroblastoma/

Researchers have shown that subtle mutational differences in a gene called ATRX help explain why children with the same type of neuroblastoma respond differently to treatment. Read more: https://www.icr.ac.uk/about-us/icr-news/detail/new-research-reveals-how-subtle-genetic-differences-shape-neuroblastoma-behaviour

Researchers at Children’s Hospital of Philadelphia (CHOP) have developed a potentially new treatment strategy aimed at immunologically “cold” tumors by restoring their ability to present antigens to the immune system. Read more: https://www.insideprecisionmedicine.com/topics/oncology/new-approach-to-treating-cold-neuroblastoma-developed/

Using machine learning and a large volume of data on genes and existing drugs, researchers at Lund University in Sweden have identified a combination of statins and phenothiazines that is particularly promising in the treatment of the aggressive form of neuroblastoma. Read more: https://medicalxpress.com/news/2025-12-machine-statin-phenothiazine-combo-neuroblastoma.html

Children with a rare form of cancer called neuroblastoma which hasn’t responded to initial treatment or that has relapsed may benefit from adding antibody treatment to usual chemotherapy, according to new results from a clinical trial. Read more: https://www.birmingham.ac.uk/news/2025/adding-antibody-treatment-to-chemo-boosts-outcomes-for-children-with-rare-cancer

A discovery from Australian researchers could lead to better treatment for children with neuroblastoma, a cancer that currently claims 9 out of 10 young patients who experience recurrence. The team at the Garvan Institute of Medical Research in Sydney, Australia, found a drug combination that can bypass the cellular defenses these tumors develop that lead to relapse. Read more: https://medicalxpress.com/news/2025-11-drug-combination-sidesteps-resistance-aggressive.html

Despite major therapeutic advances, survival rates remain lower for children from socioeconomically disadvantaged families, a pattern long observed and poorly understood at the biological level. Read more: https://medicalxpress.com/news/2025-11-food-insecurity-linked-tumor-growth.html

When the researchers increased the amount of HIF2α in neuroblastoma cells with many copies of the MYCN gene, they observed a significant reduction in MYCN protein levels. Read more: https://medicalxpress.com/news/2025-10-higher-hif2-aggressive-childhood-cancer.html